This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BRISBANE, Calif., Jan. 2, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that
Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 31st Annual J. P. Morgan Healthcare Conference in
San Francisco on
January 9, 2013, at
12:30 p.m. EST /
9:30 a.m. PST.
To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at
www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and
Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune, please visit
SOURCE InterMune, Inc.